Deals & Cases
Schellenberg Wittmer successfully represented Actavis in patent litigation against Eli Lilly
09.03.2017
Actavis, an affiliate of Teva Pharmaceutical Industries, one of the leading pharmaceutical companies worldwide, was successfully represented in a patent litigation by Schellenberg Wittmer’s IP Team (lead counsel Andrea Mondini) against Eli Lilly.
After having dismissed Eli Lilly's request for preliminary injunctions, the Swiss Federal Patent Court granted Actavis a declaratory judgment on the merits that Actavis' pemetrexed diacid product does not infringe Eli Lilly's patent EP 1 313 508 B1 claiming pemetrexed disodium for cancer treatment. This patent is heavily litigated in several countries, including Germany and the United Kingdom.
Share
Further Information
bundespatentgericht.chContact
Schellenberg Wittmer advised on the financing of ATP's acquisition of Neschen Coating
08.10.2024
Schellenberg Wittmer advised ams-OSRAM on the sale of the Passive Optical Components Assets
07.10.2024
Schellenberg Wittmer advises Meeberg Leasing Switzerland AG in a secured EUR 63 million financing transaction
26.09.2024